Fosamax and Osteonecrosis of the Jaw: Understanding Long-Term Prognosis

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Specific Medication Risks

The legacy of general health and science information has long provided a foundational framework for understanding broad physiological principles and the body’s response to external agents. Within this context, the dissemination of knowledge regarding medication safety and adverse effects has been a cornerstone, guiding both clinical practice and public awareness. This heritage established a baseline for recognizing that substances introduced into the body, whether for therapeutic or other purposes, can carry unintended consequences that manifest over time. As this informational landscape evolved, it became increasingly important to move from generalized health advisories toward more specific, context-driven risk assessments. The pivot now required is from this broad health science backdrop to a focused examination of occupational exposure scenarios. Specifically, the transition addresses the concern that individuals in certain work environments may encounter agents that influence bone metabolism and healing, thereby altering the risk profile for conditions such as osteonecrosis of the jaw. This shift in perspective necessitates a careful consideration of how workplace factors intersect with prior or concurrent medication use, particularly involving bisphosphonates like Fosamax. The goal is to reframe the discussion from a purely clinical or patient-oriented viewpoint to one that incorporates occupational health, without delving into mechanistic details, while maintaining a neutral and evidence-informed tone.

Fosamax and Osteonecrosis of the Jaw: An Overview

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation of ONJ can vary, with symptoms such as pain, swelling, or infection in the jaw, and diagnosis typically involves clinical examination and imaging. The time to onset of symptoms after starting Fosamax can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique biology of the jawbone, such as its high remodeling rate and blood supply, may contribute to susceptibility.

Prognosis and Long-Term Outcomes of ONJ After Fosamax

Regarding prognosis, most patients who develop ONJ after Fosamax use experience relief of symptoms after stopping the medication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients may have recurrence of symptoms if rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event in the osteoporosis population. Long-term outcome data from a cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests that while the relative risk increases with longer exposure, the absolute risk remains small, and prognosis improves after stopping the drug. Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a dedicated section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label advises discontinuation if severe symptoms develop and notes that most patients have relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also identifies risk factors and recommends that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Prognosis-related considerations for affected patients include the potential for symptom resolution after drug cessation, but also the possibility of recurrence with rechallenge. The timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Long-term risk increases with duration of use, but absolute risk remains low, and risk diminishes after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). For patients who develop ONJ, management typically involves conservative measures such as oral rinses, antibiotics, and avoidance of further dental surgery, with drug discontinuation being a key step. In summary, the prognosis for Fosamax-associated ONJ is generally favorable with drug cessation, though recurrence is possible with rechallenge. The risk is low in absolute terms but increases with longer exposure. Adequate warnings are provided in the prescribing information, and clinicians should consider risk factors and duration of therapy when managing patients.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after stopping Fosamax?

Most patients experience relief of symptoms after discontinuing Fosamax. However, a subset may have recurrence if rechallenged with the same or another bisphosphonate. Long-term data show that absolute risk remains low (about 0.05% after 5 years) and diminishes after stopping the drug.

How long does it take for osteonecrosis of the jaw to develop after starting Fosamax?

The time to onset of symptoms can range from one day to several months after starting Fosamax, according to the prescribing information.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.